{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:02:46Z","timestamp":1780297366648,"version":"3.54.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.7759\/cureus.110011","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:29:58Z","timestamp":1780295398000},"source":"Crossref","is-referenced-by-count":0,"title":["Multi-target Mechanisms and Clinical Evidence for Ganzaoning Granule in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Hetong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m H","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024, 9:944-56. 10.1016\/S2468-1253(24)00193-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti E","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016, 65:1038-48. 10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: the growing challenge","volume":"77","author":"Shah PA","year":"2023","unstructured":"Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: the growing challenge. Hepatology. 2023, 77:323-38. 10.1002\/hep.32542","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1476419","article-title":"Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice","volume":"11","author":"Tao SH","year":"2024","unstructured":"Tao SH, Lei YQ, Tan YM, Yang YB, Xie WN. Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice. Front Med (Lausanne). 2024, 11:1476419. 10.3389\/fmed.2024.1476419","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1675793","article-title":"Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment","volume":"16","author":"Li J","year":"2025","unstructured":"Li J, Jiao R, Su W, et al.. Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment. Front Pharmacol. 2025, 16:1675793. 10.3389\/fphar.2025.1675793","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba R","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021, 184:2537-64. 10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1558041","article-title":"Research progress on AMPK in the pathogenesis and treatment of MASLD","volume":"16","author":"Feng J","year":"2025","unstructured":"Feng J, MengHuan L, TingTing Y, XueJie Y, HaiNing G. Research progress on AMPK in the pathogenesis and treatment of MASLD. Front Immunol. 2025, 16:1558041. 10.3389\/fimmu.2025.1558041","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2024.188","article-title":"New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis","volume":"33","author":"An H","year":"2025","unstructured":"An H, Jang Y, Choi J, Hur J, Kim S, Kwon Y. New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis. Biomol Ther (Seoul). 2025, 33:18-38. 10.4062\/biomolther.2024.188","journal-title":"Biomol Ther (Seoul)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li Y","year":"2024","unstructured":"Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024, 23:117. 10.1186\/s12944-024-02108-x","journal-title":"Lipids Health Dis"},{"key":"ref16","article-title":"Effects of Ganfujian granule on the expression of cell cycle-related factors in experimental hepatocarcinogenesis in rats [Article in Chinese]","volume":"22","author":"Qian Y","year":"2001","unstructured":"Qian Y, Ling CQ, Zhao JA, et al.. Effects of Ganfujian granule on the expression of cell cycle-related factors in experimental hepatocarcinogenesis in rats [Article in Chinese]. J Fourth Mil Med Univ. 2001, 22:1587-9.","journal-title":"J Fourth Mil Med Univ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i5.755","article-title":"Preventive effect of Ganfujian granule on experimental hepatocarcinoma in rats","volume":"10","author":"Qian Y","year":"2004","unstructured":"Qian Y, Ling CQ. Preventive effect of Ganfujian granule on experimental hepatocarcinoma in rats. World J Gastroenterol. 2004, 10:755-7. 10.3748\/wjg.v10.i5.755","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos A","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020, 72:558-77. 10.1016\/j.jhep.2019.10.003","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125486","article-title":"Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives","volume":"26","author":"Fan Y","year":"2025","unstructured":"Fan Y, Liu Y, Shao C, Jiang C, Wu L, Xiao J, Tang L. Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives. Int J Mol Sci. 2025, 26:5486. 10.3390\/ijms26125486","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky J","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, et al.. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020, 17:279-97. 10.1038\/s41575-020-0269-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-024-00187-4","article-title":"From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions","volume":"10","author":"Basil B","year":"2024","unstructured":"Basil B, Myke-Mbata BK, Eze OE, Akubue AU. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol. 2024, 10:39. 10.1186\/s40842-024-00187-4","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1600439","article-title":"Gut microbiota modulation by traditional Chinese medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Zhou T","year":"2025","unstructured":"Zhou T, Jin Z, Jiang R, Li W. Gut microbiota modulation by traditional Chinese medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease. Front Pharmacol. 2025, 16:1600439. 10.3389\/fphar.2025.1600439","journal-title":"Front Pharmacol"},{"key":"ref23","article-title":"Study on pharmacodynamic material basis of Ganzaoning in treating non-alcoholic fatty liver disease based on UPLC-Q-TOF-MS\/MS and network pharmacology [Article in Chinese]","volume":"52","author":"Wang WX","year":"2021","unstructured":"Wang WX, Yao M, Yu Q, et al.. Study on pharmacodynamic material basis of Ganzaoning in treating non-alcoholic fatty liver disease based on UPLC-Q-TOF-MS\/MS and network pharmacology [Article in Chinese]. Chin Tradit Herbal Drugs. 2021, 52:3591-601.","journal-title":"Chin Tradit Herbal Drugs"},{"key":"ref24","article-title":"Preventive effect of compound Ganzaoning on non-alcoholic fatty liver in rats [Article in Chinese]","volume":"20","author":"Zhang YN","year":"2012","unstructured":"Zhang YN, Wang C, Luo MH. Preventive effect of compound Ganzaoning on non-alcoholic fatty liver in rats [Article in Chinese]. Chin J Integr Tradit West Med Dig. 2012, 20:119-22.","journal-title":"Chin J Integr Tradit West Med Dig"},{"key":"ref25","article-title":"Influence of Ganfujian granule formula on process of liver fibrosis in rat [Article in Chinese]","volume":"24","author":"Qian Y","year":"2003","unstructured":"Qian Y, Ling CQ. Influence of Ganfujian granule formula on process of liver fibrosis in rat [Article in Chinese]. J Fourth Mil Med Univ. 2003, 24:1905-7.","journal-title":"J Fourth Mil Med Univ"},{"key":"ref26","article-title":"Effect of Ganfujian granule on collagen deposition in rat liver fibrosis [Article in Chinese]","volume":"21","author":"Qian Y","year":"2002","unstructured":"Qian Y, Ling CQ, Jin Y. Effect of Ganfujian granule on collagen deposition in rat liver fibrosis [Article in Chinese]. J Anhui Univ Chin Med. 2002, 21:36-7.","journal-title":"J Anhui Univ Chin Med"},{"key":"ref27","article-title":"Effects of Ganfujian granule on C-myc IGF-II gene expression in rat hepatocarcinogenesis [Article in Chinese]","volume":"23","author":"Qian Y","year":"2002","unstructured":"Qian Y, Ling CQ, Jin Y. Effects of Ganfujian granule on C-myc IGF-II gene expression in rat hepatocarcinogenesis [Article in Chinese]. J Fourth Mil Med Univ. 2002, 23:1702-4.","journal-title":"J Fourth Mil Med Univ"},{"key":"ref28","article-title":"Mechanism of Ganfujian granule inhibiting hepatocarcinogenesis induced by diethylnitrosamine in rats [Article in Chinese]","volume":"27","author":"Qian Y","year":"2003","unstructured":"Qian Y, Jin Y, Li Y, et al.. Mechanism of Ganfujian granule inhibiting hepatocarcinogenesis induced by diethylnitrosamine in rats [Article in Chinese]. J Zhejiang Chin Med Univ. 2003, 27:56-8.","journal-title":"J Zhejiang Chin Med Univ"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.5428\/pcar20180211","article-title":"Efficacy observation of Ganzaoning granules in the treatment of nonalcoholic steatohepatitis [Article in Chinese]","volume":"18","author":"Zhang XY","year":"2018","unstructured":"Zhang XY, Peng H, Wang HZ, et al.. Efficacy observation of Ganzaoning granules in the treatment of nonalcoholic steatohepatitis [Article in Chinese]. Pharm Care Res. 2018, 18:123-6.","journal-title":"Pharm Care Res"},{"key":"ref30","article-title":"Clinical efficacy and safety analysis of Ganzaoning granules in the treatment of nonalcoholic fatty liver disease [Article in Chinese]","volume":"20","author":"Lu JY","year":"2017","unstructured":"Lu JY, Zheng GY, Peng H, et al.. Clinical efficacy and safety analysis of Ganzaoning granules in the treatment of nonalcoholic fatty liver disease [Article in Chinese]. J Pract Hepatol. 2017, 20:556-7.","journal-title":"J Pract Hepatol"},{"key":"ref31","article-title":"Analysis of Syndrome Characteristics of Patients with Chronic HBV Infection Complicated with Fatty Liver and Study on the Therapeutic Effect of Traditional Chinese Medicine Ganzaoning","author":"Yu Q","year":"2020","unstructured":"Yu Q. Analysis of Syndrome Characteristics of Patients with Chronic HBV Infection Complicated with Fatty Liver and Study on the Therapeutic Effect of Traditional Chinese Medicine Ganzaoning. Shanghai University of Traditional Chinese Medicine, Shanghai; 2020."},{"key":"ref32","article-title":"Effect of Ganzaoning Recipe on Non-alcoholic Fatty Liver Disease: A Clinical Trial and Experimental Study","author":"Peng H","year":"2020","unstructured":"Peng H. Effect of Ganzaoning Recipe on Non-alcoholic Fatty Liver Disease: A Clinical Trial and Experimental Study. Naval Medical University, Shanghai; 2020."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475620-multi-target-mechanisms-and-clinical-evidence-for-ganzaoning-granule-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:30:00Z","timestamp":1780295400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475620-multi-target-mechanisms-and-clinical-evidence-for-ganzaoning-granule-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.110011","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}